Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy-Reference-Cited by-同舟云学术

Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy

Published:2007-08 Issue:8 Volume:18 Page:1363-1368
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

El Gnaoui T,Dupuis J,Belhadj K,Jais J-P,Rahmouni A,Copie-Bergman C,Gaillard I,Diviné M,Tabah-Fisch I,Reyes F,Haioun C

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/18/8/1363/19446218/mdm133.pdf

Reference34 articles.

1. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma;Philip;N Engl J Med,1995

2. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial;Schouten;J Clin Oncol,2003

3. Long-term follow-up of platinum-based lymphoma salvage regimens. The M.D. Anderson Cancer Center experience;Rodriguez-Monge;Hematol Oncol Clin North Am,1997

4. Preclinical, pharmacologic, and phase I studies of gemcitabine;Storniolo;Semin Oncol,1997

5. Gemcitabine as a single agent in the treatment of relapsed or refractory low-grade non-Hodgkin's lymphoma;Dumontet;Br J Haematol,2001

Cited by 135 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ibrutinib in Combination with R-GemOx in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma of Nongerminal Center B-cell–like Type: Phase II Clinical Trial of the Spanish GELTAMO Group;Clinical Cancer Research;2024-06-20

2. Rituximab, gemcitabine and oxaliplatin in relapsed or refractory indolent and mantle cell lymphoma: results of a multicenter phase I/II-study of the German Low Grade Lymphoma Study Group;Annals of Hematology;2024-03-09

3. Navigating between Scylla and Charybdis: A roadmap to do better than Pola-RCHP in DLBCL;Cancer Treatment Reviews;2024-03

4. Use of gemcitabine, oxaliplatin, and anti‐CD20 therapy in children and adolescents with non‐Hodgkin lymphoma unfit for intensive therapy;Pediatric Blood & Cancer;2023-01-24

5. Systematic review of outcomes and patient heterogeneity in relapsed or refractory diffuse large B-cell lymphoma;Journal of Comparative Effectiveness Research;2023-01